May 15, 2018 01:01 PM EDT
Pharma

Pfiz­er fi­nal­ly fin­ish­es a 3-year reg­u­la­to­ry odyssey, bag­ging an FDA OK for 1st Epogen knock­off

John Carroll

Editor & Founder

A decade af­ter Hos­pi­ra launched its biosim­i­lar of Am­gen’s ag­ing ane­mia drug Epogen in Eu­rope, its suc­ces­sors at Pfiz­er have fi­nal­ly pushed it over the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

For­mer Pfiz­er CEO and CFO flip on ac­tivist and say they now sup­port com­pa­ny

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

A service from the Financial Times